Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776305 | 0.95 | CPB2 (0.49) | CPB2CPB1ITGB3ITGA2BSLC15A2 | |
| SCHEMBL3839540 | 0.89 | CPB2 (0.55) | CPB2CPB1SLC15A2 | |
| SCHEMBL3845157 | 0.89 | CPB2 (0.55) | CPB2CPB1SLC15A2 | |
| SCHEMBL30978072 | 0.87 | CPB2 (0.51) | CPB2CPB1ITGB3ITGA2BTLR2 | |
| SCHEMBL19138220 | 0.87 | CPB2 (0.51) | CPB2CPB1ITGB3ITGA2BTLR2 | |
| SCHEMBL38650912 | 0.87 | CPB2 (0.51) | CPB2CPB1ITGB3ITGA2BTLR2 | |
| SCHEMBL29503862 | 0.87 | CPB2 (0.51) | CPB2CPB1ITGB3ITGA2BTLR2 | |
| SCHEMBL19138219 | 0.87 | CPB2 (0.51) | CPB2CPB1ITGB3ITGA2BTLR2 | |
| SCHEMBL1667027 | 0.87 | CPB2 (0.51) | CPB2CPB1ITGB3ITGA2BTLR2 | |
| SCHEMBL11499161 | 0.87 | CPB2 (0.40) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | INNOVATIVE VISION PRODUCTS, INC. (US) | 2014-03-27 | — | — | US | claimed |
| US-20220395489-A1 | THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-15 | — | — | US | disclosed |
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | INNOVATIVE VISION PRODUCTS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20110151053-A1 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACID SEQUENCES ENCODING PROTEASE HOMOLOGUES AND USES THEREFORE | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-06-23 | — | — | US | disclosed |
| US-7897367-B2 | Lactobacillus acidophilus nucleic acid sequences encoding protease homologues and uses therefore | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20110020900-A1 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACID SEQUENCES ENCODING PROTEASE HOMOLOGUES AND USES THEREFORE | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| EP-1122307-B1 | Human carnosinase 2 | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | disclosed |
| US-7455992-B2 | Lactobacillus acidophilus nucleic acid sequences encoding protease homologues and uses therefore | NORTH CAROLINA STATE UNIVERSITY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1871868-A2 | METHODS AND COMPOSITIONS TO MODULATE ADHESION AND STRESS TOLERANCE IN BACTERIA | North Carolina State University (US) | 2008-01-02 | — | — | EP | disclosed |
| US-7186816-B2 | Photolyase nucleic acids | THE GENERAL HOSPITAL CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070003667-A1 | Lactobacillus acidophilus nucleic acid sequences encoding protease homologues and uses therefore | NORTH CAROLINA STATE UNIVERSITY | 2007-01-04 | — | — | US | disclosed |
| WO-2006113475-A2 | METHODS AND COMPOSITIONS TO MODULATE ADHESION AND STRESS TOLERANCE IN BACTERIA | NORTH CAROLINA STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060116328-A1 | Combined use of carnosinase inhibitor with l-carnosines and composition | INNOVATIVE VISION PRODUCTS, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1586332-A1 | COMBINED USE OF CARNOSINASE INHIBITOR WITH L-CARNOSINES AND COMPOSITION | Innovative Vision Products, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005081959-A2 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACID SEQUENCES ENCODING PROTEASE HOMOLOGUES AND USES THEREFOR | NORTH CAROLINA STATE UNIVERSITY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20040214208-A1 | Enterococcal virulence factors | GENERAL HOSPITAL CORPORATION, THE | 2004-10-28 | — | — | US | disclosed |
| US-6632636-B1 | Use of vectors, host cells and methods for producing Moraxella catarrhalis proteins, or portions thereof, for identification of diagnostic and therapeutic compositions | ELITRA PHARMACEUTICALS INC. | 2003-10-14 | — | — | US | disclosed |
| WO-2003056295-A2 | ENTEROCOCCAL VIRULENCE FACTORS | THE GENERAL HOSPITAL CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| EP-1122307-A1 | Human carnosinase 2 | SANOFI-SYNTHELABO (FR) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116328-A1 | Combined use of carnosinase inhibitor with l-carnosines and composition | LCT, ADH1C, PON1 | CPB2 550/4885CPB1 223/4885ITGB3 4835/4885 |
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | LCT, CPA1, ADH1C | CPB2 379/4885CPB1 146/4885ITGB3 4842/4885 |
| US-20220395489-A1 | THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE | FABP2, SI, VIP | CPB2 90/4885CPB1 130/4885ITGB3 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.